Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 42/100

Affimed NV at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 03:30PM GMT
Release Date Price: $43.75 (-3.74%)
Amy Shin

Good morning, everyone. My name is Amy Shin, and I'm part of the health care team at JPMorgan. It is with great pleasure that I introduce Dr. Adi Hoess, CEO of Affimed. And with that, I'll hand it off to Dr. Hoess. Thank you.

Adi Hoess
Affimed N.V. - CEO, MD & Member of Management Board

Thank you, Amy, for the introduction and good day, all, for listening today to my presentation about Affimed.

And as you may well know, we are actualizing an untapped potential in the immune system called the innate immune system. We believe that this can indeed drive a revolution in cancer treatment as the innate immune system has a very good potential, in particular with the activation of natural killer cells and macrophages. You may not only be able to drive these cells to attack the tumor, but also kick off the entire immune system, comprising also the adaptive components such as T cells. Overall, it should improve patients' lives and ideally also lead to some cures.

We do this by developing bispecific innate cell engagers. Why do we call them

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot